Lupin Digital Health unveils results of first digital therapeutics study with ACS patients

DTx interventions led to 83 per cent patients bringing and maintaining their vitals in normal range

Lupin Digital Health (LDH) has unveiled the results of a study in India, showing the efficacy of digital therapeutics (DTx) among patients with Acute Coronary Syndrome (ACS) and post-percutaneous coronary interventions. The study findings were presented at the India Live 2023 symposium in Chennai.

LDH, a wholly-owned subsidiary of Lupin recently launched its digital therapeutics platform, Lyfe, evidence-based holistic heart care program that significantly reduces the risk of a heart attack and improves the quality of life for cardiac patients.

The one-year-long study was aimed to evaluate the efficacy of LDH’s digital therapeutics platform, Lyfe, on cardiovascular events, rehospitalisation, medication adherence, vital sign monitoring, and lifestyle changes among heart patients. During the 90-day interim analysis, patients enrolled in the program demonstrated significant improvement, with 90 per cent adhering to the recommended medication, diet, and exercise regimen. 83.3 per cent of patients maintained their vital signs within the normal range, and no re-hospitalisations occurring during the first 30 days of enrolment.

The study results indicate that digital therapeutics programs will have a crucial role in patient care across the cardiology continuum, powered by technology. These results showcase a promising future for remote patient care in cardiology, utilising the potential of digital health to improve patients’ heart health.